Technology ID
TAB-4549

DLX3-floxed mice (DLX3f/f) for Use in Drug Development and In Vivo Research Studies for Ectodermal Dysplasia Disorders

E-Numbers
E-012-2015-0
Lead Inventor
Morasso, Maria (NIAMS)
Applications
Research Materials
Therapeutic Areas
Dermatology
Development Stages
Pre-clinical (in vivo)
Research Products
Animal Models
Lead IC
NIAMS
ICs
NIAMS

This technology includes the creation of DLX3-floxed mice, specifically designed for conditional deletion of the DLX3 gene via Cre-mediated recombination. This innovative approach aims to develop mouse models for studying ectodermal dysplasia disorders. Ectodermal dysplasias are a diverse group of genetic conditions affecting the development of ectodermal structures, including hair, teeth, and bones. The DLX3f/f mice are particularly valuable for modeling specific disorders such as Tricho-dento-osseous syndrome (TDO), Amelogenesis Imperfecta (AI), and Dentinogenesis Imperfecta (DI). By selectively ablating the DLX3 gene, the genetic and phenotypic aspects of these disorders can be closely mimicked, enhancing our understanding and potentially leading to new therapeutic strategies.

Commercial Applications
A potential use of DLX3f/f mice is for the generation of mouse models for ectodermal dysplasia disorders, perform targeted drug development, and to study molecular mechanisms of DLX3 regulation in skin and ectodermal appendages.

Competitive Advantages
Floxed DLX3 allele allows conditional knockout of this gene in different tissues at specific time during development.

Request More Info

Licensing Contact:
Knezevic, Vladimir
vlado.knezevic@nih.gov

Collaborations

  • Materials Available
  • Licensing

Collaboration Description

  • We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology.
Date Published